Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.40 |
| ▸ | AURKA | O14965 | 6/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927694 | 0.85 | GSK3B (0.47) | KDRAURKAAURKBMAPTCHEK1 | |
| SCHEMBL6426104 | 0.85 | LMNA (0.48) | KDRAURKAHDAC3HDAC1HDAC2 | |
| SCHEMBL6426772 | 0.83 | KDR (0.45) | KDRAURKAAURKBHDAC3HDAC1 | |
| SCHEMBL6427153 | 0.83 | KDR (0.41) | KDRAURKAAURKBFGFR1MAPT | |
| SCHEMBL6426452 | 0.82 | KDR (0.44) | KDRAURKAAURKBFGFR1MAPT | |
| SCHEMBL5032367 | 0.81 | KDR (0.44) | KDRAURKAAURKBFGFR1MAPT | |
| SCHEMBL6426066 | 0.81 | MAPK10 (0.42) | KDRAURKAAURKBHDAC3HDAC1 | |
| SCHEMBL6426295 | 0.81 | AURKA (0.40) | KDRAURKAAURKBFGFR1MAPT | |
| SCHEMBL6427662 | 0.81 | AURKA (0.44) | KDRAURKAAURKBFGFR1CHEK1 | |
| SCHEMBL6427897 | 0.80 | ULK1 (0.43) | KDRAURKAAURKBFGFR1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | KDR 932/4885AURKA 726/4885AURKB 608/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | KDR 1044/4885AURKA 710/4885AURKB 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.